CA2990791A1 - Therapeutic agent for fibrosis - Google Patents
Therapeutic agent for fibrosis Download PDFInfo
- Publication number
- CA2990791A1 CA2990791A1 CA2990791A CA2990791A CA2990791A1 CA 2990791 A1 CA2990791 A1 CA 2990791A1 CA 2990791 A CA2990791 A CA 2990791A CA 2990791 A CA2990791 A CA 2990791A CA 2990791 A1 CA2990791 A1 CA 2990791A1
- Authority
- CA
- Canada
- Prior art keywords
- fibrosis
- amino
- fibrillation
- present
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015-127788 | 2015-06-25 | ||
| JP2015127788 | 2015-06-25 | ||
| PCT/JP2016/068902 WO2016208744A1 (ja) | 2015-06-25 | 2016-06-24 | 線維症治療剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2990791A1 true CA2990791A1 (en) | 2016-12-29 |
Family
ID=57585165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2990791A Pending CA2990791A1 (en) | 2015-06-25 | 2016-06-24 | Therapeutic agent for fibrosis |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US10449189B2 (enExample) |
| EP (2) | EP3315131B1 (enExample) |
| JP (3) | JP6974167B2 (enExample) |
| KR (1) | KR102647942B1 (enExample) |
| CN (2) | CN107708697B (enExample) |
| AU (1) | AU2016284531B2 (enExample) |
| BR (1) | BR112017028137B1 (enExample) |
| CA (1) | CA2990791A1 (enExample) |
| DK (1) | DK3315131T3 (enExample) |
| ES (1) | ES2928684T3 (enExample) |
| HU (1) | HUE060732T2 (enExample) |
| MA (1) | MA42266A (enExample) |
| MX (2) | MX381792B (enExample) |
| MY (1) | MY191219A (enExample) |
| PH (1) | PH12017502322B1 (enExample) |
| PL (1) | PL3315131T3 (enExample) |
| PT (1) | PT3315131T (enExample) |
| RU (1) | RU2729630C2 (enExample) |
| SG (2) | SG10201912684TA (enExample) |
| WO (1) | WO2016208744A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007139608A1 (en) | 2006-03-14 | 2007-12-06 | Ceres, Inc. | Nucleotide sequences and corresponding polypeptides conferring modulated growth rate and biomass in plants grown in saline conditions |
| US12152246B2 (en) | 2006-03-14 | 2024-11-26 | Ceres, Inc. | Nucleotide sequences and corresponding polypeptides conferring modulated growth rate and biomass in plants grown in saline conditions |
| BR112017028137B1 (pt) * | 2015-06-25 | 2023-04-04 | Taiho Pharmaceutical Co., Ltd | Uso de 4-[2-fluoro-4-[[[(2-fenilacetil)amino]tioxometil]amino]- fenóxi]-7-metóxi-n-metil-6-quinolinacarboxamida ou um sal deste |
| DK3583943T3 (da) | 2017-02-15 | 2024-10-14 | Taiho Pharmaceutical Co Ltd | Farmaceutisk sammensætning |
| EP3682882A4 (en) | 2017-09-08 | 2021-06-02 | Taiho Pharmaceutical Co., Ltd. | ANTI-TUMOR AGENT AND ANTI-TUMOR POTENTIALIZER |
| KR20210060465A (ko) | 2018-09-18 | 2021-05-26 | 다이호야쿠힌고교 가부시키가이샤 | 아실티오우레아 화합물과 아비라테론의 병용 요법 |
| TWI872203B (zh) * | 2020-02-14 | 2025-02-11 | 日商大鵬藥品工業股份有限公司 | 醯基硫脲化合物的製造方法 |
| CN115177636A (zh) * | 2022-07-18 | 2022-10-14 | 陕西科美致尚生物科技有限公司 | 一种用于治疗前列腺钙化的组合物及其制备方法与应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4094814B2 (ja) | 1998-04-28 | 2008-06-04 | 敏一 中村 | 血管新生抑制剤 |
| JP2003238592A (ja) * | 2001-12-13 | 2003-08-27 | Japan Tobacco Inc | 組織及び血管の再生のための医薬及びその方法 |
| EP1896461A2 (en) | 2005-06-30 | 2008-03-12 | Amgen Inc. | Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer |
| ZA200804681B (en) * | 2005-11-30 | 2009-11-25 | Vertex Pharma Inc | Inhibitors of C-Met and uses thereof |
| US7728017B2 (en) * | 2005-11-30 | 2010-06-01 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Met and uses thereof |
| CA2676173A1 (en) | 2007-02-16 | 2008-08-28 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors |
| EP2215085B1 (en) * | 2007-10-25 | 2011-09-07 | AstraZeneca AB | Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders |
| JP4667537B2 (ja) | 2008-04-10 | 2011-04-13 | 大鵬薬品工業株式会社 | アシルチオウレア化合物又はその塩、及びその用途 |
| UY32049A (es) * | 2008-08-14 | 2010-03-26 | Takeda Pharmaceutical | Inhibidores de cmet |
| MX2012008898A (es) * | 2010-02-03 | 2012-11-06 | Incyte Corp | Imidazo - [1, 2 - b] [1, 2, 4] triazinas como inhibidores de c - met. |
| JP5960688B2 (ja) | 2010-05-17 | 2016-08-02 | インコゼン セラピューティクス プライベート リミテッド | プロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物 |
| TWI594986B (zh) | 2011-12-28 | 2017-08-11 | Taiho Pharmaceutical Co Ltd | Antineoplastic agent effect enhancer |
| RU2494470C1 (ru) * | 2012-04-04 | 2013-09-27 | Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "Саентифик Фьючер Менеджмент") | Способ лечения фиброза легких |
| US9149471B2 (en) | 2013-09-30 | 2015-10-06 | National University Corporation Tokyo University Of Agriculture And Technology | Therapeutic agent for osteoporosis |
| BR112017028137B1 (pt) * | 2015-06-25 | 2023-04-04 | Taiho Pharmaceutical Co., Ltd | Uso de 4-[2-fluoro-4-[[[(2-fenilacetil)amino]tioxometil]amino]- fenóxi]-7-metóxi-n-metil-6-quinolinacarboxamida ou um sal deste |
-
2016
- 2016-06-24 BR BR112017028137-6A patent/BR112017028137B1/pt active IP Right Grant
- 2016-06-24 WO PCT/JP2016/068902 patent/WO2016208744A1/ja not_active Ceased
- 2016-06-24 CA CA2990791A patent/CA2990791A1/en active Pending
- 2016-06-24 MY MYPI2017704204A patent/MY191219A/en unknown
- 2016-06-24 PT PT168145134T patent/PT3315131T/pt unknown
- 2016-06-24 SG SG10201912684TA patent/SG10201912684TA/en unknown
- 2016-06-24 CN CN201680037175.7A patent/CN107708697B/zh active Active
- 2016-06-24 EP EP16814513.4A patent/EP3315131B1/en active Active
- 2016-06-24 JP JP2017525457A patent/JP6974167B2/ja active Active
- 2016-06-24 SG SG11201709260TA patent/SG11201709260TA/en unknown
- 2016-06-24 PL PL16814513.4T patent/PL3315131T3/pl unknown
- 2016-06-24 DK DK16814513.4T patent/DK3315131T3/da active
- 2016-06-24 AU AU2016284531A patent/AU2016284531B2/en active Active
- 2016-06-24 PH PH1/2017/502322A patent/PH12017502322B1/en unknown
- 2016-06-24 EP EP21205221.1A patent/EP3973962A1/en not_active Withdrawn
- 2016-06-24 US US15/574,060 patent/US10449189B2/en active Active
- 2016-06-24 HU HUE16814513A patent/HUE060732T2/hu unknown
- 2016-06-24 MX MX2017016774A patent/MX381792B/es unknown
- 2016-06-24 ES ES16814513T patent/ES2928684T3/es active Active
- 2016-06-24 MA MA042266A patent/MA42266A/fr unknown
- 2016-06-24 KR KR1020177033481A patent/KR102647942B1/ko active Active
- 2016-06-24 CN CN202110067291.6A patent/CN112716952A/zh active Pending
- 2016-06-24 RU RU2017145271A patent/RU2729630C2/ru active
-
2017
- 2017-12-19 MX MX2020012989A patent/MX2020012989A/es unknown
-
2019
- 2019-09-17 US US16/573,362 patent/US10695340B2/en active Active
-
2020
- 2020-06-02 US US16/889,870 patent/US11191759B2/en active Active
-
2021
- 2021-10-29 US US17/513,946 patent/US11690838B2/en active Active
- 2021-11-04 JP JP2021180108A patent/JP7258985B2/ja active Active
-
2023
- 2023-04-05 JP JP2023061284A patent/JP7498827B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11690838B2 (en) | Therapeutic agent for fibrosis | |
| JP5302900B2 (ja) | 脂肪性肝疾患の治療用医薬組成物 | |
| EP3858351B1 (en) | Tolperisone and eperisone for use in the treatment of pulmonary fibrosis | |
| HK40046439A (en) | Therapeutic agent for fibrosis | |
| US9707219B2 (en) | Losmapimod for use in treating glomerular disease | |
| JPWO2017217071A1 (ja) | セレノプロテインｐ活性阻害作用を有する成分を含有する、肺高血圧症の予防又は治療剤 | |
| HK1245639B (en) | Therapeutic agent for fibrosis | |
| RU2451507C2 (ru) | Лекарственное средство для лечения хронического обструктивного заболевания легких | |
| CN121443299A (zh) | 用于治疗脏器纤维化相关疾病的药物组合物和方法 | |
| HK1140136B (en) | A medicament for treating chronic obstructive pulmonary disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210319 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20240815 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241127 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250203 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD Year of fee payment: 9 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250514 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250514 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250530 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250530 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251003 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251003 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B302 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - CONDITIONS FOR GRANT DETERMINED NOT COMPLIANT Effective date: 20260203 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260721 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260806 |